Skip to main content
SpringerLink
Log in

Gynecological Tumors

  • Chapter
  • First Online:
Hybrid PET/CT and SPECT/CT Imaging

Abstract

Gynecological cancers as a group comprise approximately 11% of female cancer (1). In the United States, it is estimated that nearly 78,290 women will be diagnosed in 2007 with gynecological cancers and that approximately 28,000 women will die as a result of these cancers (accounting for 10% of all cancer-related deaths in women). Gynecological cancers are typically diagnosed by history, physical examination, and selected imaging studies. There has been an increasing use of PET using 18,F-fluorodeoxyglucose (FDG) for staging and restaging of these cancers, as well as for assessing response to therapy (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.

    Google Scholar 

  2. Lai CH, Yen TC, Chang TC. Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 2007;19:37–41.

    Article  PubMed  Google Scholar 

  3. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005;97:183–191.

    Article  PubMed  Google Scholar 

  4. Choi HJ, Roh JW, Seo SS, Lee S, Kim J-Y, Kim S-K, Kang KW, Lee JS, Jeong JY, Park S-Y. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: A prospective study. Cancer 2006;106:914–922.

    Article  PubMed  Google Scholar 

  5. Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, Nedergaard L, Højgaard L Engelholm SA. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007;106:29–34.

    Article  PubMed  Google Scholar 

  6. Wright JD, Dehdashti F, Herzog TJ, Mutch DG, Huettner PC, Rader JS, Gibb RK, Powell MA, Gao F, Siegel BA, Grigsby PW. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005;104:2484–2491.

    Article  PubMed  Google Scholar 

  7. Chou HH, Chang TC, Yen TC, Ng K-K, Hsueh S, Ma S-Y, Chang C-J, Huang H-J, Chao A, Wu T-I, Jung S-M, Wu Y-C, Lin C-T, Huang K-G, Lai C-H. Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J Clin Oncol 2005;24:123–128.

    Article  Google Scholar 

  8. Sironi S, Buda A, Picchio M, Perego P, Moreni R, Pellegrino A, Colombo M, Mangioni C, Messa C, Fazio F. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 2005;238:272–279.

    Article  PubMed  Google Scholar 

  9. Lin LL, Mutic S, Low DA, LaForest R, Vicic M, Zoberi I, Miller T, Grigsby P. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys 2007;67:91–96.

    Article  PubMed  Google Scholar 

  10. Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol 2007;12:165–175.

    Article  PubMed  Google Scholar 

  11. Panici PB, Cutillo G, Angioli R. Modulation of surgery in early invasive cervical cancer. Crit Rev Oncol Hematol 2003;48:263–270.

    Article  PubMed  Google Scholar 

  12. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:353–359.

    Article  PubMed  Google Scholar 

  13. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 2007;110:1738–1744.

    Article  PubMed  Google Scholar 

  14. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001;19:3745–3749.

    CAS  PubMed  Google Scholar 

  15. Chung HH, Jo H, Kang WJ, Kim JW, Park N-H, Song Y-S, Chung J-K, Kang S-B, Lee H-P. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529–534.

    Article  PubMed  Google Scholar 

  16. Yen TC, Lai CH, Ma SY, Huang K-G,  Huang H-J,  Hong J-H,  Hsueh S,  Lin W-J, Ng K-K, Chang T-C. Comparative benefits and limitations of (18)F-FDG PET and CT-MRI in documented or suspected recurrent cervical cancer. Eur J Nucl Med Mol Imaging 2006;33:1399–1407.

    Article  PubMed  Google Scholar 

  17. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome. J Clin Oncol 2004;22:2167–2171.

    Article  PubMed  Google Scholar 

  18. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007;298:2289–2295.

    Article  CAS  PubMed  Google Scholar 

  19. Johnson RJ. Radiology in the management of ovarian cancer. Clin Radiol 1993;48:75–82.

    Article  CAS  PubMed  Google Scholar 

  20. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: Assessment by PET/CT. J Nucl Med 2004;45:266–271.

    PubMed  Google Scholar 

  21. Grab D, Flock F, Stohr I, Nüssle K, Rieber A, Fenchel S, Brambs H-J, Reske SN, Kreienberg R. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454–459.

    Article  CAS  PubMed  Google Scholar 

  22. Yoshida Y, Kurokawa T, Kawahara K, Tsuchida T, Okazawa H, Fujibayashi Y, Yonekura Y, Kotsuji F. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am J Roentgenol 2004;182:227–233.

    PubMed  Google Scholar 

  23. Castellucci P, Perrone AM, Picchio M, Ghi T, Farsad M, Nanni C, Messa C, Meriggiola M, Pelusi G, Al-Nahhas A, Rubello D, Fazio F, Fanti S. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007;28:589–595.

    Article  CAS  PubMed  Google Scholar 

  24. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521–528.

    Article  PubMed  Google Scholar 

  25. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003;88:9–16.

    Article  CAS  PubMed  Google Scholar 

  26. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA, Werner M, Graeff H, Schwaiger M, Kuhn W. Prediction of response to neoadjuvant chemotherapy by sequential F-18-Fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445–7453.

    Article  PubMed  Google Scholar 

  27. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman E, Wahl RL, Montz FJ. Clinically occult recurrent ovarian cancer: Patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003;90:519–528.

    Article  PubMed  Google Scholar 

  28. Chung HH, Kang WJ, Kim JW, Park N-H,  Song Y-S, Chung J-K,  Kang S-B, Lee H-P. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur J Nucl Med Mol Imaging 2007;34:480–486.

    Article  PubMed  Google Scholar 

  29. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol 2006;103:271–276.

    Article  PubMed  Google Scholar 

  30. Zhuang H, Yamamoto AJ, Sinha P, Pourdehnad M, Liu Y, Alavi A. Similar pelvic abnormalities on FDG positron emission tomography of different origins. Clin Nucl Med 2001;26:515–517.

    Article  CAS  PubMed  Google Scholar 

  31. Lee WL, Liu RS, Yuan CC, Chao HT, Wang PH. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: Preliminary findings on positron emission tomography. Fertil Steril 2001;75:638–639.

    Article  CAS  PubMed  Google Scholar 

  32. Horowitz NS, Dehdashti F, Herzog TJ, Rader JS, Powell MA, Gibb RK, Grigsby PW, Siegel BA, Mutch DG. Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546–551.

    Article  PubMed  Google Scholar 

  33. Suzuki R, Miyagi E, Takahashi N, Sukegawa A, Suzuki A, Koike I, Sugiura K, Okamoto N, Inoue T, Hirahara F. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int J Gynecol Cancer 2007;17:890–896.

    Article  CAS  PubMed  Google Scholar 

  34. Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1132–1139.

    Article  CAS  PubMed  Google Scholar 

  35. Saga T, Higashi T, Ishimori T, Marcelo M. Yuji N, Takahiro M, Toru F, Kaori T, Shigeo Y, Toshihiro H, Masato K, Shingo F, Junji K. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med 2003;17:197–203.

    Article  PubMed  Google Scholar 

  36. Podoloff DA, Ball DW, Ben-Josef E, Benson AB, Cohen SJ, Coleman RE, Delbeke D, Ho M, Ilson DH, Kalemkerian GP, Lee RJ, Loeffler JS, Macapinlac HA, Morgan RJ, Siegel BA, Singhal S, Tyler DS, Wong RJ. NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types Task Force. J Natl Compr Canc Netw 2009;7 Suppl 2:S1–S23. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

    Google Scholar 

  37. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: Clinical considerations. Eur J Cancer 2006;42:2296–2302.

    Article  PubMed  Google Scholar 

  38. Sartori E, Pasinetti B, Carrara L, Gambino A, Odicino F, Pecorelli S. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 2007;107:S241–247.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA

    Farrokh Dehdashti MD (Professor of Radiology)

  2. Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center Washington University School of Medicine, Saint Louis, MO, USA

    Barry A. Siegel MD

Authors
  1. Farrokh Dehdashti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry A. Siegel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Farrokh Dehdashti MD .

Editor information

Editors and Affiliations

  1. Medical Center, Vanderbilt University, 21st Ave. S. & Garland 1161, Nashville, 37232-2675, U.S.A.

    Dominique Delbeke

  2. Dept. Nuclear Medicine, Rambam Medical Centre, Bat-Galim, Haifa, 35 254, Israel

    Ora Israel

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Dehdashti, F., Siegel, B.A. (2010). Gynecological Tumors. In: Delbeke, D., Israel, O. (eds) Hybrid PET/CT and SPECT/CT Imaging. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92820-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-92820-3_10

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-92819-7

  • Online ISBN: 978-0-387-92820-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation